Genenta Science (NASDAQ:GNTA) Earns “Buy” Rating from HC Wainwright

Genenta Science (NASDAQ:GNTA)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a report released on Wednesday, Benzinga reports. They currently have a $25.00 price target on the stock. HC Wainwright’s price target would suggest a potential upside of 496.66% from the stock’s current price.

Genenta Science Price Performance

GNTA stock traded up $0.11 during mid-day trading on Wednesday, hitting $4.19. 1,022 shares of the company were exchanged, compared to its average volume of 8,218. The firm has a fifty day simple moving average of $4.13 and a 200 day simple moving average of $3.66. Genenta Science has a twelve month low of $2.20 and a twelve month high of $5.87.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Genenta Science stock. AlTi Global Inc. acquired a new position in Genenta Science S.p.A. (NASDAQ:GNTA) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 200,288 shares of the company’s stock, valued at approximately $621,000. AlTi Global Inc. owned 1.10% of Genenta Science at the end of the most recent reporting period. 15.13% of the stock is owned by institutional investors and hedge funds.

Genenta Science Company Profile

Genenta Science S.p.A., a clinical-stage biotechnology company, engages in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors in Italy. Its lead product candidate is Temferon, which is in Phase 1/2a clinical trials for use in the treatment of glioblastoma multiforme in patients with unmethylated MGMT gene promoter.